Abbott Laboratories (ABT) Capital Expenditures (2009 - 2026)

Abbott Laboratories' Capital Expenditures history runs 18 years deep, the most recent figure standing at $399.0 million for Q1 2026.

• In Q1 2026, Capital Expenditures fell 17.56% year-over-year to $399.0 million; the TTM figure through Mar 2026 stood at $2.1 billion (down 9.03% YoY), while the FY2025 annual figure was $2.2 billion, down 1.63% from the prior year.
• Capital Expenditures came in at $399.0 million for Q1 2026 at Abbott Laboratories, down from $689.0 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $755.0 million in Q4 2023 to a low of $321.0 million in Q1 2022.
• A 5-year average of $515.1 million and a median of $502.0 million in 2025 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures retreated 19.14% in 2022 and soared 33.77% in 2023, its largest moves.
• Abbott Laboratories' Capital Expenditures stood at $610.0 million in 2022, then gained by 23.77% to $755.0 million in 2023, then retreated by 4.64% to $720.0 million in 2024, then dropped by 4.31% to $689.0 million in 2025, then sank by 42.09% to $399.0 million in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $399.0 million, $689.0 million, and $496.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison